These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19959082)

  • 1. Treatment strategies for CML.
    Goldman JM
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):303-13. PubMed ID: 19959082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An advance in the treatment of CML].
    Ohnishi K
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2185-90. PubMed ID: 18079618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging treatment options in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
    Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line management of CML: a state of the art review.
    Hochhaus A
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imatinib therapy for patients with chronic myelogenous leukemia].
    Usui N
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing therapy of chronic myeloid leukemia.
    Deininger MW
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):144-54. PubMed ID: 17379100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
    J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
    Zonder JA; Schiffer CA
    Curr Hematol Rep; 2003 Jan; 2(1):57-64. PubMed ID: 12901155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
    Goldman J
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Getting to the stem of chronic myeloid leukaemia.
    Savona M; Talpaz M
    Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
    Ruiz-Argüelles GJ; Tarin-Arzaga LC; Gonzalez-Carrillo ML; Gutierrez-Riveroll KI; Rangel-Malo R; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D; Giralt S
    Bone Marrow Transplant; 2008 Jul; 42(1):23-8. PubMed ID: 18612313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Kantarjian H; Talpaz M; O'Brien S; Giles F; Rios MB; White K; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Kornblau S; Cortes J
    Cancer; 2003 May; 97(9):2225-8. PubMed ID: 12712475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.